Uscom (UCM) today informed shareholders that Spacelabs Healthcare intend to launch Uscom in the United Kingdom market on 1 October 2009. As part of their global distribution agreement with Uscom Ltd, Spacelabs Healthcare are planning the product launch of the USCOM 1A into the UK. This is an important step in the global USCOM rollout as the UK is a sophisticated bio-device market already sensitized to the USCOM technology.
Uscom has established some early milestones in the UK with Key Opinion Leaders using the product and publishing peer reviewed papers on the device, and dedicated market support already in country. Spacelabs are building their capability in the UK to enhance these early positive steps that Uscom has already made. To support this UK push Uscom is planning some specific joint marketing activities in the UK in the coming months to further activate the acceptance and take-up of the USCOM product.
Uscom Limited is an Australian medical device company which was first listed on the Australian Stock Exchange in December 2003. Uscom has developed a Non Invasive Cardiac Output Monitor. The USCOM is a simple, cost-effective and non-invasive device that measures heart function, detects irregularities and guides treatment. The USCOM device has major applications in Paediatrics, Emergency Medicine, Intensive Care Units and Anesthesia, and is a tool of choice for management of adult and paediatric sepsis, and for the guidance of all fluid administration.
USCOM has global regulatory approval and the technology is currently marketed in North America, South America, Europe, the Middle East, India and Australia by Spacelabs Healthcare, while in China and SE Asia USCOM is distributed by Pacific Medical Systems and in New Zealand it is distributed by MedXus.
Tags: Biotechnology, Distribution Agreement, Healthcare, ucm, Uscom
